New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
06:59 EDTVSTMVerastem data compelling, says Cantor
After Verastem reported data from its Phase Ib combination study of defactinib in combination with docetaxel for the treatment of ovarian cancer, Cantor remains upbeat about the company's overall pipeline. It keeps a $22 price target and Buy rating on the stock.
News For VSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
07:16 EDTVSTMMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 12, 2014
08:13 EDTVSTMBoston Biotech to hold a conference
Subscribe for More Information
November 7, 2014
07:10 EDTVSTMVerastem says data on PYK2 inhibition by VS-4718 in MM published
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use